JPMorgan Chase & Co. Issues Positive Forecast for Stoke Therapeutics (NASDAQ:STOK) Stock Price

Stoke Therapeutics (NASDAQ:STOK) had its target price upped by JPMorgan Chase & Co. from $15.00 to $25.00 in a report published on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.

STOK has been the topic of a number of other reports. Wedbush boosted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. BTIG Research boosted their target price on Stoke Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Stoke Therapeutics in a research report on Wednesday, October 8th. Chardan Capital reiterated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Finally, Needham & Company LLC boosted their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $26.10 on Monday. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $38.69. The company has a market cap of $1.43 billion, a PE ratio of 30.71 and a beta of 1.32. The stock’s 50 day moving average price is $26.16 and its 200 day moving average price is $16.86.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The firm had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. On average, equities research analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 45,996 shares of the business’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the transaction, the director directly owned 91,585 shares of the company’s stock, valued at $1,843,606.05. The trade was a 33.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Barry Ticho sold 5,501 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total value of $109,304.87. Following the completion of the transaction, the insider directly owned 18,469 shares of the company’s stock, valued at approximately $366,979.03. This trade represents a 22.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 180,676 shares of company stock valued at $4,071,664 over the last three months. 9.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Siren L.L.C. increased its stake in Stoke Therapeutics by 12.4% in the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock valued at $14,945,000 after purchasing an additional 247,347 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Stoke Therapeutics during the second quarter worth about $402,000. KLP Kapitalforvaltning AS lifted its position in Stoke Therapeutics by 131.6% during the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock worth $150,000 after buying an additional 7,500 shares during the period. Invesco Ltd. lifted its position in Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after buying an additional 14,118 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Stoke Therapeutics during the first quarter worth about $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.